Navigation Links
UCLA researchers clarify function of glucose transport molecule
Date:7/3/2008

Researchers at the David Geffen School of Medicine at UCLA have solved the structure of a class of proteins known as sodium glucose co-transporters (SGLTs), which pump glucose into cells. These transport proteins are used in the treatment of chronic diarrhea via oral rehydration therapy, saving the lives of millions of children each year. The solution of the SGLT structure will accelerate development of new drugs designed to treat patients with diabetes and cancer.

Led by Jeff Abramson and Ernest Wright of the UCLA Department of Physiology, the research team produced an "atomic snap shot" of an SGLT protein. Using a specialized technique known as X-ray crystallography, they and their team of post-docs and students generated the first high-resolution, three-dimensional picture of a glucose transport protein. The research is published in today's online edition of the journal Science.

"This was a very challenging study that required innovation at each step of the process," said Abramson. "We literally had to invent new approaches to entice the protein into a crystal and then spent years optimizing these crystals to reach a quality suitable for visualization by X-rays. This would not have been possible without high-throughput protein production and purification capabilities."

A tantalizing observation made during the determination of the glucose transporter structure was the possibility for structural similarities with a previously crystallized neurotransmitter transporter molecule. Exploiting these similarities, along with computer modeling of structural dynamics, the researchers obtained the first atomic-level evidence for the mechanism underlying transport of glucose and neurotransmitters (such as serotonin) into cells. These results provide a fundamental understanding of how membrane proteins function in a dynamic manner.

Pharmaceutical companies already have extensive clinical trials underway to evaluate the use of inhibitors targeting SGLT1 and SGLT2 proteins to control blood glucose levels in diabetic patients by blocking intestinal glucose absorption and increasing glucose excretion into the urine. The UCLA findings will dramatically enhance the ability to rationally design these drugs.

In ongoing work, Wright and Abramson are examining the manner in which inhibitors of the transporter proteins modulate function with the goal of facilitating better drug design for the treatment of diabetes, obesity, and cancer.


'/>"/>

Contact: Elaine Schmidt
eschmidt@mednet.ucla.edu
310-794-2272
University of California - Los Angeles
Source:Eurekalert

Related biology news :

1. Researchers identify proteins involved in new neurodegenerative syndrome
2. Texas researchers and educators head for Antarctica
3. MGH researchers describe new way to identify, evolve novel enzymes
4. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
5. U of MN researchers discover noninvasive diagnostic tool for brain diseases
6. U of Minnesota researchers discover noninvasive diagnostic tool for brain diseases
7. Researchers discover new strategies for antibiotic resistance
8. Researchers find new taste in fruit flies: carbonated water
9. Binghamton University researchers investigate evolving malaria resistance
10. UIC researchers find promising new targets for antibiotics
11. Researchers develop simple method to create natural drug products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017 MedNet ... that supports the entire spectrum of clinical research, ... another record-breaking year for the organization in terms ... in MedNet,s eClinical products and services. The company,s ... marketplace success of iMedNet ...
(Date:1/12/2017)... , January 12, 2017 A new report by Allied Market ... the global biometric technology market is expected to generate revenue of $10.72 billion by ... Continue Reading ... Allied Market Research Logo ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) ...
(Date:1/6/2017)... Jan. 5, 2017  SomaLogic announced today that ... Alliance" established by iCarbonX, the China ... a "Global Digital Health Ecosystem that can define ... of individual,s biological, behavioral and psychological data, the ... the companies, SomaLogic will provide proteomics data and ...
Breaking Biology News(10 mins):
(Date:1/18/2017)... ... January 18, 2017 , ... Executive ... 2017 in its continued commitment to the advancement of the clinical trials segment. ... issues related to clinical trial planning and management. , As executive talent ...
(Date:1/18/2017)... FL (PRWEB) , ... January 18, 2017 , ... ... weakness and paralysis, today announced that it has submitted a 510(k) to the ... bikes that utilize MYOLYN’s patent-pending functional electrical stimulation (FES) technology. , The ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... the latest paper by its Science Editor, Dr. Elisabeth Bik, in the December ... Microbiologie). Dr. Bik joined uBiome in October 2016 from her previous position at ...
(Date:1/18/2017)... 18, 2017  Caris Life Sciences, a leading ... the largest private funder of pancreatic cancer research, ... the impact of immunotherapy in the treatment of ... services to identify potential trial candidates based on ... physicians and study investigators. The Lustgarten Foundation is ...
Breaking Biology Technology: